Is Revance Therapeutics Inc (RVNC) Stock About to Get Hot Friday?

The market has been neutral on Revance Therapeutics Inc (RVNC) stock recently. RVNC gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Revance Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on RVNC!

See Full RVNC Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With RVNC Stock Today?

Revance Therapeutics Inc (RVNC) stock has fallen -4.09% while the S&P 500 is up 0% as of 2:38 PM on Friday, Mar 22. RVNC is lower by -$0.21 from the previous closing price of $5.19 on volume of 481,565 shares. Over the past year the S&P 500 has risen 33.14% while RVNC is lower by -84.33%. RVNC lost -$3.83 per share in the over the last 12 months.

More About Revance Therapeutics Inc

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products. Click Here to get the full Stock Report for Revance Therapeutics Inc stock.